International AI Industry Alliance (AIIA) Successfully Hosts First Biomedicine Committee Seminar at Peking University Science and Technology Park
January 17, 2025
The AIIA, in alignment with the recent Central Economic Work Conference'semphasis on driving new quality productive forces through technologicalinnovation and building a modern industrial system, successfully held its firstseminar of the AIIA Biomedicine Committee on January 17, 2025, at PekingUniversity Science and Technology Park. The seminar, themed "GainingInsights into New AI Trends, Exploring the Future," aimed to foster discussionson the integration of artificial intelligence into the biomedicine sector.
The morning session commenced with Dr. Deng Zhongming, President of Peking University Science and Technology Park, Dean of the Institute of Industrial Technology Research, and Executive Vice Chairman of AIIA, introducing Peking University's industrial layout in Shenzhen. Dr. Deng highlighted the park's transformation into an AI-focused hub through the Peking University AI4S initiative and AIIA. The park has applied for a silver economy industrial park centered on "AI+ Health" and will focus on AI+ industry applications and pilot testing. Dr. Deng emphasized AI as the future direction, noting AIIA's extensive network of over 800 academicians, universities, investment institutions, enterprises, associations, and projects. The AIIA Shenzhen Center, established on December 26, 2024, has launched the AI Innovation Brain platform and initiated preparations for the AI+ Instruments and AI+ Biomedicine Committees, signing strategic cooperation agreements with Tsinghua University's Technology Innovation Center, Guangdong Academy of Sciences' Guangke Holdings, Forbes China's AI Enterprise Selection Organizing Committee, and Skyworth Business School to enhance resource integration and accelerate the Greater Bay Area's AI transformation and technological innovation.
Zhou Sihua, CEO of Kaiyuan Cloud Technology, shared an AI case study on "The Current Status and Future Opportunities of Computing Power." Zhou discussed the critical role of computing power in the digital economy, analyzing the strengths of China and the U.S. in this area and highlighting the significant market potential in China, along with challenges such as power consumption, integration, operation, and application. Zhou introduced Kaiyuan Cloud Technology's open-computing platform, which provides professional computing cloud services to government, enterprise clients in universities, scientific research, large models, and AI, forming an integrated solution of "cloud + network + computing + application."
Yang Xiaodong, CEO of Shuzhi Biosciences, focused on "Common Paradigms and Business Practices of Algorithms." Yang emphasized the need for collaborative efforts to address complex real-world tasks, introducing LabVerse, an AI data science intelligent agent that makes data science accessible and rediscovers the value of real-world data. Yang showcased AI's empowerment of the medical industry, improving analysis efficiency and meeting various real-world trial requirements. LabVerse is currently undergoing internal testing with its first batch of users, and the project is seeking financing due to its significant market potential.
Wu Kejian, Head of Research at Dali Capital, presented a case analysis of "Investment Trends in the AI Track." Wu outlined the seven main development stages of AI, with deep learning remaining the core driver of AI progress. He identified healthcare, autonomous driving, and finance as leading areas of AI penetration. Wu also provided an in-depth analysis of domestic AI investment trends, focusing on upstream computing power, midstream basic large models, and downstream industry applications as key investment areas.
Yang Xiaodong, initiator of the AIIA Biomedicine Committee, shared the "AIIA Biomedicine Committee Plan." Yang emphasized the committee's role in promoting the deep integration of AI and biomedicine, accelerating technological innovation and the transformation of results. The committee aims to build a cross-field communication platform, promote the formulation of standards and specifications, and focus on key areas to drive innovative applications. Yang highlighted the committee's importance in driving industrial transformation and fostering global collaboration to explore new paths for the integrated development of AI and biomedicine, contributing to the cause of human health.
The AIIA Biomedicine Committee is dedicated to promoting the deep integration and application of artificial intelligence (AI) technology in the biomedicine field. With the rapid development of AI technology, its applications in drug research and development, disease diagnosis, personalized treatment, and healthcare management are becoming increasingly widespread, profoundly impacting the traditional pharmaceutical industry. To capture this transformative trend, AIIA has established the Biomedicine Committee, aiming to accelerate technological innovation, facilitate the transformation of research outcomes, and enhance the intelligent level of the global biomedicine industry.